Cited by 955Parkinson's Disease Mechanisms and TreatmentsNerve injury and regenerationNuclear Receptors and Signaling

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Functional recovery in parkinsonian monkeys treated with GDNF

Gash, Don M., Zhang, Zhiming, Ovadia, Aliza, Cass, Wayne A., Yi, Ai, Simmerman, Linda, Russell, Deborah, Martin, David, Lapchak, Paul A., Collins, Frank, Hoffer, Barry J., Gerhard, Greg A.·1996·Nature

DOI 10.1038/380252a0

Open this paper in CoChat — free account

Abstract

Parkinson's disease results from the progressive degeneration of dopamine neurons that innervate the striatum. In rodents, glial-cell-line-derived neurotrophic factor (GDNF) stimulates an increase in midbrain dopamine levels, protects dopamine neurons from some neurotoxins, and maintains injured dopamine neurons. Here we extend the rodent studies to an animal closer to the human in brain organization and function, by evaluating the effects of GDNF injected intracerebrally in rhesus monkeys that have had the symptomatology and pathophysiological features of Parkinson's disease induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The recipients of GDNF displayed significant improvements in three of the cardinal symptoms of parkinsonism: bradykinesia, rigidity and postural instability. GDNF administered every four weeks maintained functional recovery. On the lesioned side of GDNF-treated animals, dopamine levels in the midbrain and globus pallidus were twice as high, and nigral dopamine neurons were, on average, 20% larger, with an increased fibre density. The results indicate that GDNF may be of benefit in the treatment of Parkinson's disease.

Integrity signals

Registry

Crossref · 10.1038/380252a0

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons
Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206
Self-citation
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079
Self-citation
New stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940
Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 850
Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain
Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A., & Hefti, F. F. (1995) · Nature · doi:10.1038/373339a0 · Cited by 654
A consideration of neural counting methods
Coggeshall, R. E. (1992) · Trends in Neurosciences · doi:10.1016/0166-2236(92)90339-a · Cited by 540
Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo
Hoffer, B. J., Hoffman, A. F., Bowenkamp, K., Huettl, P. F., Hudson, J., Martin, D., Lin, L.-F. H., & Gerhardt, G. A. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90218-6 · Cited by 453
Self-citation
GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo
Kearns, C. M., & Gash, D. M. (1995) · Brain Research · doi:10.1016/0006-8993(94)01366-p · Cited by 379
Self-citation
Hemiparkinsonism in monkeys after unilateral internal carotid artery artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Bankiewicz, K. S., Oldfield, E. H., Chiueh, C. C., Doppman, J. L., Jacobowitz, D. M., & Kopin, I. J. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90431-5 · Cited by 308

Flagged first, then by citations

Show all 22 references

Research works printed but not linked: 2

Jellinger, K. Adv. Neurol. 45, 1–18 (1986).
Hornykiewicz, O. & Kish, S. J. Adv. Neurol. 45, 19–34 (1986).

Sorted by citations

Items 801–900 of 946

Therapeutic Application of Stem Cell and Gene Therapy in Parkinson’s Disease
Palmer, C., Coronel, R., Bernabeu-Zornoza, A., & Liste, I. (2018) · Springer eBooks · doi:10.1007/978-981-13-0944-1_14 · Cited by 4
Functional Effects of GDNF in Normal and Parkinsonian Rats and Monkeys
Hebert, M. A., Hoffer, B. J., Zhang, Z., Cass, W. A., Hoffman, A. F., Gash, D. M., & Gerhardt, G. A. (1999) · Elsevier eBooks · doi:10.1016/b978-012705070-6/50016-0 · Cited by 4
Self-citation
Recovery after nigral grafting in 6-hydroxydopamine lesioned rats is due to graft function and not significantly influenced by the remaining ipsilateral or contralateral host dopaminergic system
López-Martín, M. E., Rozas, G., Guerra, M. J., & Labandeira-García, J. L. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01853-3 · Cited by 4
Neurotrophic Factors and Amyotrophic Lateral Sclerosis
Sendtner, M. (1999) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-59920-0_4 · Cited by 4
Bidirectional Relationship between the BDNF Gene and miRNA: Implications for PD Pathogenesis
Elangovan, A., Iyer, M., HariKrishnaReddy, D., Wander, A., Kinoshita, M., Krishnan, J., & Vellingiri, B. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00173 · Cited by 4
Parkinson's Disease: Cell Vulnerability and Disease Progression
de Tassigny, X. D., Pascual, A., & López‐Barneo, J. (2015) · Frontiers research topics · doi:10.3389/978-2-88919-676-0 · Cited by 3
GDNF and Related Proteins
Peterziel, H., & Strelau, J. (2006) · Springer eBooks · doi:10.1007/0-387-30395-2_4 · Cited by 3
Similarities and Differences in Cognitive Deficits and Responsiveness to L-Dopa between Aged and MPTP-Treated Cynomolgus Monkeys Tested on the Same Tasks
Zhang, Z., & Weeks, R. (2014) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.1000188 · Cited by 3
Self-citation
Gene Therapy for Parkinson’s Disease: AAV5-Mediated Delivery of Glial Cell Line-Derived Neurotrophic Factor (GDNF)
Blits, B., Kirik, D., Petry, H., & Hermening, S. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_3 · Cited by 3
Intestinal flora imbalance affects the prognosis of Parkinson's disease by regulating the expression of fecal microRNA-146a and GDNF: A Preliminary Study
Wei, H., Hu, Y., & Yang, L. (2021) · Archives of Medical Science · doi:10.5114/aoms/143780 · Cited by 3
Developing an MRI-Based Biomarker for Early Diagnosis of Parkinson's Disease
Jorge, E. C., Wang, X., & Zhang, Z. (2011) · InTech eBooks · doi:10.5772/18458 · Cited by 3
Self-citation
GDNF: a Key Player in Neuron-Glia Crosstalk and Survival of Nigrostriatal Dopaminergic Neurons
Duarte, E. P., Saavedra, A., & Baltazar, G. (2007) · Springer eBooks · doi:10.1007/978-0-387-70830-0_8 · Cited by 3
Growth Factors in Alzheimer’s Disease
Nagahara, A. H., & Tuszynski, M. H. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_15 · Cited by 3
EFFECTS OF INTRANASALLY ADMINISTERED DNSP-11 ON THE CENTRAL DOPAMINE SYSTEM OF NORMAL AND PARKINSONIAN FISCHER 344 RATS
Sonne, J. H. (2013) · UKnowledge (University of Kentucky) · Cited by 3
Targeting Tyrosine Hydroxylase to Improve Bradykinesia
Michael, F. (2012) · InTech eBooks · doi:10.5772/16699 · Cited by 3
Neurotrophic factors and Parkinson's disease
Gash, D. M., Chen, Y., & Gerhardt, G. A. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83025-9 · Cited by 3
Self-citation
INCREASED EXPRESSION OF GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR IN RAT BRAIN AFTER TRAUMATIC
Injury, B., Rahimi-movaghar, V., Yan, H. Q., Li, Y., Ma, X., Akbarian, F., & Dixon, C. E. (2005) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 3
A Gene Therapy Approach for the Treatment of Amyotrophic Lateral Sclerosis and Parkinson's Disease
Zurn, A. D., Tseng, J., Déglon, N., Joseph, J., & Aebischer, P. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60899-6 · Cited by 3
Prospects for new drug treatment in idiopathic parkinsonism
Samii, A., Letwin, S. R., & Calne, D. B. (1998) · Drug Discovery Today · doi:10.1016/s1359-6446(97)01158-6 · Cited by 3
Molecular Etiology of Parkinson Disease: Recent Progress
Shastry, B. S. (2000) · The Neuroscientist · doi:10.1177/107385840000600406 · Cited by 3
In vivo regulation of glial cell line-derived neurotrophic factor-inducible transcription factor by kainic acid
Eisch, A. J., Lammers, C.-H., Yajima, S., Mouradian, M. M., & Nestler, E. J. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00302-4 · Cited by 3
Trophic Influences on Neural Tissue Transplants
Granholm, A. (2000) · Neuromethods · doi:10.1007/978-1-59259-690-4_18 · Cited by 3
Freshwater Clam Extract Mitigates Neuroinflammation and Amplifies Neurotrophic Activity of Glia: Insights from In Vitro Model of Neurodegenerative Pathomechanism
Lin, M.-S., Chen, S., Hua, K., Chen, W., Hsieh, C.-C., & Lin, C.-C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030553 · Cited by 2
Disease-specific interventions: The use of cell and gene therapies for Parkinson disease
Barker, R. A., & Buttery, P. C. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00003-4 · Cited by 2
Motor learning is regulated by postnatal GDNF levels in Purkinje cells
Nagaeva, E. I., Turconi, G., Mätlik, K., Segerstråle, M., Olfat, S., Iivanainen, V., Taira, T., & Andressoo, J. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.04.030 · Cited by 2
Intraparenchymal Drug Delivery for Parkinson’s Disease
Penn, R. D., & Linninger, A. A. (2009) · Springer eBooks · doi:10.1007/978-3-540-69960-6_103 · Cited by 2
Chemical Anatomy and Synaptic Connectivity of the Globus Pallidus and Subthalamic Nucleus
Smith, Y., Charara, A., Hanson, J. E., Hubert, G. W., & Kuwajima, M. (2001) · Springer eBooks · doi:10.1007/978-1-4615-1235-6_10 · Cited by 2
Oxidative Stress in Parkinson's Disease; Parallels Between Current Animal Models, Human Studies and Cells
Norazit, A., Mellick, G. D., & Meedeniy, A. C. B. (2012) · InTech eBooks · doi:10.5772/33459 · Cited by 2
Dopamine-synthesizing neurons: An overview of their development and application for cell therapy
Gardaneh, M. (2010) · Iranian Journal of Biotechnology · Cited by 2
Growth and Neurotrophic Factor Receptors in Neural Differentiation and Phenotype Specification
Glaser, T., Oliveira‐Giacomelli, Á., Sardà‐Arroyo, L., & Ulrich, H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800781-5.00007-4 · Cited by 2
RESTORATION OF MOTOR AND NON-MOTOR FUNCTIONS BY NEUROTROPHIC FACTORS IN NONHUMAN PRIMATES WITH DOPAMINE DEPLETION
Subramanian, K. (2013) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 2
Experimental study on heterograft of glomus cells of carotid body for hemiparkinsonian rats
Xuebing, C., Shenggang, S., & E-tang, T. (2002) · Current Medical Science · doi:10.1007/bf02857674 · Cited by 2
STUDIES OF THE EFFECTS OF DOPAMINE NEURON STIMULATING PEPTIDES IN RODENT MODELS OF NORMAL AND DYSFUNCTIONAL DOPAMINERGIC SYSTEMS
Fuqua, J. L. (2010) · UKnowledge (University of Kentucky) · Cited by 2
The Surgical Management of Parkinson’s Disease
Hickey, P., & Stacy, M. A. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.25 · Cited by 2
Selective reduction of the intermolecular disulfide bridge in human glial cell line-derived neurotrophic factor using tris-(2-carboxyethyl) phosphine
Hui, J. O., Le, J. C., Katta, V., Rohde, M. F., & Haniu, M. (1997) · Techniques in protein chemistry · doi:10.1016/s1080-8914(97)80029-4 · Cited by 2
Chapter 34 Towards gene therapy of neurodegenerative disease
Federoff, H. J., & Atkinson, M. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)64035-2 · Cited by 2
Encapsulated Cell Implants as a Novel Treatment for Parkinson's Disease
Tseng, J., & Aebischer, P. (2003) · Humana Press eBooks · doi:10.1385/1-59259-142-6:279 · Cited by 2
Intranasal delivery of GDNF for the treatment of Parkinson's disease
Migliore, M. M. (2008) · doi:10.17760/d10018463 · Cited by 2
Genetic Engineering for Parkinson's Disease
Eberling, J. L., Major, E. O., Nagy, D., & Bankiewicz, K. S. (1999) · Elsevier eBooks · doi:10.1016/b978-012705070-6/50017-2 · Cited by 2
Is Trophic Factor Gene Disruption a “Knockout” Model for Parkinson’s Disease?
Granholm, A., & Hoffer, B. J. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-691-1_13 · Cited by 2
Self-citation
Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Self-citation
Phosphodiesterase Inhibition Increases Striatal GDNF and Protects Against Preclinical Parkinsonism
de Tassigny, X. D., Jiménez‐Medina, A., López‐López, I., & López‐Barneo, J. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70321 · Cited by 1
Inhibition of TGF-beta signaling protects from alpha-synuclein induced toxicity
Chua, O. W. H., Duan, L., Bothe, S., Evsyukov, V., Moebius, C., Bickle, M., Höglinger, G. U., & Höllerhage, M. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02901-2 · Cited by 1
Gene Transfer for Parkinson’s Disease
Starr, P. A., & Bankiewicz, K. S. (2009) · Springer eBooks · doi:10.1007/978-3-540-69960-6_102 · Cited by 1
STEM CELL THERAPIES FOR PARKINSON'S DISEASE
Androutsellis‐Theotokis, A., Rueger, M. A., & McKay, R. D. G. (2008) · Elsevier eBooks · doi:10.1016/b978-012373994-0.50008-7 · Cited by 1
La thérapie génique dans la maladie de Parkinson : un traitement d’avenir ?
Golé, C., Reboul, R., & Pisano, P. S. (2011) · Therapies · doi:10.2515/therapie/2011062 · Cited by 1
GDNF-Induced Expression of Tyrosine Hydroxylase
Kiuchi, K., & Xiao, H. (2002) · Advances in behavioral biology · doi:10.1007/978-1-4757-3538-3_24 · Cited by 1
Surgical treatment of Parkinson disease and other movement disorders
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00007-x · Cited by 1
Epigenetics, Stem Cells, Cellular Differentiation, and Associated Neurological Disorders and Brain Cancer
Srinageshwar, B., Dunbar, G. L., & Rossignol, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91909-8.00029-3 · Cited by 1
Fundamental Research On and Practical Application Of GDNF as a Neuroprotective Agent in Neurodegenerative Diseases
Shamadykova, D., & Pavlova, G. V. (2025) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-025-01807-x · Cited by 1
NIGROSTRIATAL DOPAMINE-NEURON FUNCTION FROM NEUROTROPHIC-LIKE PEPTIDE TREATMENT AND NEUROTROPHIC FACTOR DEPLETION
Littrell, O. M. (2011) · UKnowledge (University of Kentucky) · Cited by 1
Restorative Therapies for Parkinson's Disease: Current Status and Future Perspectives
Björklund, A. (2006) · Springer eBooks · doi:10.1007/0-387-32823-2_1 · Cited by 1
Parkinson's disease: molecular aspects and prospective neuroprotective and restorative therapies
Montiel, H., & Hernández-Montiel, H. L. (2006) · Archivos de Neurociencias · Cited by 1
Epigenetics, Stem Cells, Cellular Differentiation, and Associated Hereditary Neurological Disorders
Srinageshwar, B., Maiti, P., Dunbar, G. L., & Rossignol, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805388-1.00021-3 · Cited by 1
Impact of the Aged Brain Environment on Gene Therapy for Parkinson’s Disease
Polinski, N. K., Fischer, D. L., Duffy, M. F., Manfredsson, F. P., Kemp, C. J., Steece‐Collier, K., & Sortwell, C. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00048-8 · Cited by 1
Spatial and temporal immunoreactivity in the rat brain using an affinity purified polyclonal antibody to DNSP-11
Sonne, J., Groshong, J. S., Seavey, C., & Gash, D. M. (2019) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2019.101664 · Cited by 1
Self-citation
Surgical treatment of Parkinson disease and other movement disorders
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00007-x · Cited by 1
Neurosurgical Approaches: Drug Infusion Directly into the Parenchyma or the Cerebrospinal Fluid
Bankiewicz, K. S. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7_18 · Cited by 1
NOVEL CDNF/MANF PROTEIN FAMILY: MOLECULAR STRUCTURE, EXPRESSION AND NEUROTROPHIC ACTIVITY
Lindholm, P. (2009) · Työväentutkimus Vuosikirja · Cited by 1
Approaches in the treatment of Parkinson's disease : a focus on stem cell-based therapies.
Al-Maqtari, T. (2012) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/34 · Cited by 1
ROLE OF GDNF AND ITS CROSS-TALK WITH OTHER GROWTH FACTORS IN THE DOPAMINERGIC SYSTEM
Planken, A. (2012) · Työväentutkimus Vuosikirja · Cited by 1
Age Effects in Substantia Nigra of Asian Indians
Alladi, P. A. (2013) · Wiley eBooks · doi:10.1002/9781118444177.ch3 · Cited by 1
GDNF and p75 Neurotrophin Receptor in Development and Disease
Wartiovaara, K. (1998) · Työväentutkimus Vuosikirja · Cited by 1
Neurotrophic Factors as Novel Therapeutic Targets
Skaper, S. D. (2011) · Wiley eBooks · doi:10.1002/9780470571224.pse458 · Cited by 1
The Potential of Neurotrophic Factors for the Treatment of Parkinson’s Disease
Aideen, M. E., & Toulouse, A. (2011) · InTech eBooks · doi:10.5772/16659 · Cited by 1
Dopaminergic Neurons Derived from Human Embryonic Stem Cell Derived Neural Progenitors: Biological Relevance and Application
Young, A., & Stice, S. L. (2011) · InTech eBooks · doi:10.5772/15242 · Cited by 1
Prevention of Calbindin Recruitment into Nigral Dopamine Neurons from MPTP-Induced Degeneration in Macaca fascicularis
Takada, M., Inoue, K., Miyachi, S., Okado, H., & Nambu, A. (2009) · Advances in behavioral biology · doi:10.1007/978-1-4419-0340-2_29 · Cited by 1
Terapias neuroprotectoras y neurorestauradoras en el tratamiento de la enfermedad de Parkinson
Garbayo, E., Aymerich, M. S., Ansorena, E., Lanciego, J. L., & Blanco‐Prieto, M. J. (2006) · Anales del Sistema Sanitario de Navarra · doi:10.4321/s1137-66272006000500002 · Cited by 1
Ex Vivo Gene Therapy in the Central Nervous System
Blesch, A., & Tuszynski, M. H. (2002) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-06274-6_11 · Cited by 1
GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR AND NEURTURIN IN THE REGULATION OF SPERMATOGENESIS
Meng, X. (2001) · Työväentutkimus Vuosikirja · Cited by 1
DIRECT DELIVERY OF GDNF INTO THE NON-HUMAN PRIMATE AND HUMAN PARKINSONIAN BRAIN: SUCCESS AND ROAD BLOCKS
Grondin, R., Zhang, Z., Ai, Y., Slevin, J. T., Young, A. B., Gash, D. M., & Gerhardt, G. A. (2008) · Elsevier eBooks · doi:10.1016/b978-012373994-0.50011-7 · Cited by 1
Self-citation
CIBLAGE ASTROCYTAIRE DE L'EXPRESSION DU GDNF PAR DES LENTIVECTEURS POUR UNE THERAPIE GENIQUE DE PROTECTION DE LA MALADIE DE PARKINSONPreprint
Mammeri, H. (2006) · Cited by 1
Functional Effects of GDNFon Dopamine Neurons in Animal Models of Parkinson’s Disease
Hoffman, A. F., Hebert, M. A., Hoffer, B. J., Zhang, Z., Cass, W. A., Gash, D. M., & Gerhardt, G. A. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_86 · Cited by 1
Self-citation
Opportunities and Challenges of the Therapies Targeting CNS Regeneration
Perez, H. D., Mitrovic, B., & Evercooren, A. B. (2005) · Springer eBooks · doi:10.1007/3-540-27626-2 · Cited by 1
Adipose-derived mesenchymal stem cells: neuronal differentiation potential and neuroprotective action.
Anghileri, E. (2010) · Cited by 1
Olfactory Stem Cells From Adult Rats
Wetzig, A. R. (2007) · Griffith Research Online · doi:10.25904/1912/907 · Cited by 1
Erythropoietin as a Modulator of Pathology in a Toxicant Mouse Model of Parkinson’s Disease
Thompson, A. (2019) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2019-13782 · Cited by 1
Advances in Disease Modifying Therapies for Parkinson's Disease
Hassanzadeh, K., & Mouradian, M. M. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch2 · Cited by 1
Gene Therapy for Parkinson's Disease
Lawlor, P. A. (2006) · Elsevier eBooks · doi:10.1016/b978-012397632-1/50009-5
Einfluss des GDNF-Rezeptors RET auf die akute MPTP-Toxizität in der Maus
Kowsky, S. (2011) · doi:10.53846/goediss-1073
Parkinson-Krankheit: Pathophysiologie und pathogenetische Faktoren
Jellinger, K. A. (1999) · Springer eBooks · doi:10.1007/978-3-7091-6400-6_1
Structure and function of GDNF receptor alpha splice variants
Yang, J. (2006) · Työväentutkimus Vuosikirja
Molecular and Cellular Characterization of Dopamine Neuron Stimulating Peptides
Kelps, K. A. (2013) · UKnowledge (University of Kentucky)
Cell-Based and Gene-Based Therapy for Parkinson's Disease
Olanow, C. W. (2009) · Blue books of neurology · doi:10.1016/b978-1-4160-6641-5.00017-9
Pathophysiology: biochemistry of Parkinson's disease
Berg, D., Rieß, O., & Riederer, P. F. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544873.042
Immunhistochemische und neurochemische Untersuchungen zur Rolle von Dopamin im Globus pallidus der Ratte
Fuchs, H. (2002) · OPUS Publication Server of the University of Stuttgart (University of Stuttgart) · doi:10.18419/opus-1575
Place de l'activation microgliale associée à la dégénérescence des neurones dopaminergiques provoquée par la 6-OHDA chez le rat : implication dans la compréhension de la pathogénie de la maladie de Parkinson
Henry, V. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)
Activity-Dependent Regulation of the Dopamine Phenotype in the Adult Substantia Nigra: Prospects for Treating Parkinson's Disease
Horne, M., Lord, K., & Aum, T. (2012) · InTech eBooks · doi:10.5772/35221
Glial Cell Line-derived Neurotrophic Factor, Neurturin and their Receptors in the Development, Maintenance and Plasticity of the Nervous System
Laurikainen, A. (2000) · Työväentutkimus Vuosikirja
Regulated GDNF Delivery in Vivo Using Neural Stem Cells
Svendsen, C. N. (2004) · doi:10.21236/ada428919
CNS Drug Delivery for Movement Disorders
Penn, R. D., & Kroin, J. S. (2000) · KARGER eBooks · doi:10.1159/000062041
Gene-supplemented collagen scaffolds for non-viral gene delivery for brain tissue engineering
Bolliet, C. (2007) · DSpace@MIT (Massachusetts Institute of Technology)
Structure-Function Studies of GDNF Family Ligand-RET signalling
Virtanen, H. (2009) · Työväentutkimus Vuosikirja
Generation of Dopaminergic Neurons from Human Embryonic Stem Cells
Vazin, T. (2008) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Pharmacotherapy and Treatment of Parkinson's Disease
Au, W. L., & Calne, D. B. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn062
Einfluss des GDNF-Rezeptors Ret auf die Erholung des nigrostriatalen Systems im MPTP-Mausmodell der Parkinsonerkrankung
Pöppelmeyer, C. (2011) · doi:10.53846/goediss-990
Biology of glial cell-line derived neurotrophic factor
Maswood, N., & Gash, D. M. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8354-2_7
Self-citation
Dopaminergic System: Selected Advances and Emerging Potential Therapeutic Targets
Ghanemi, A. (2013) · International Journal of Public Health Science (IJPHS) · doi:10.11591/ijphs.v2i2.3070
La vitamina D regula la expresión del factor neurotrófico GDNF en cultivos neuronales estriatales y en ratas normales y hemiparkinsonianas
Rey, B. (2014) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Studies on peripheral nervous system development and function in mice lacking the neurturin receptor GFRα2
Kupari, J. (2015) · Työväentutkimus Vuosikirja · doi:10.13140/rg.2.1.1546.6726

Authors: Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., Hoffer, B. J., & Gerhard, G. A.
Affiliations: University of Kentucky (US)
ORCID: Gash, Don M.
Zhang, Zhiming
Cass, Wayne A.
Lapchak, Paul A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1996-03
Volume: 380
Issue: 6571
Pages: 252-255
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/380252a0
OpenAlex: W1971258758
Cited by: 955
References: 22
Citations by year: 2026: 2 · 2025: 12 · 2024: 10 · 2023: 9 · 2022: 20 · 2021: 16 · 2020: 23 · 2019: 18 · 2018: 20 · 2017: 13 · 2016: 21 · 2015: 27 · 2014: 24 · 2013: 30 · 2012: 27
FWCI: 51.18
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, glial cell line-derived neurotrophic factor, MPTP-induced parkinsonism, rhesus monkeys, dopaminergic neurons, midbrain dopamine, globus pallidus, nigral neurons, bradykinesia, rigidity, postural instability, functional recovery, neuroprotection, neurotrophic therapy
MeSH terms: Animals, Dopamine, Female, Humans, Macaca mulatta, Mesencephalon, Nerve Growth Factors, Nerve Tissue Proteins, Neurons, Parkinson Disease, Recombinant Proteins, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Glial Cell Line-Derived Neurotrophic Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Functional recovery in parkinsonian monkeys treated with GDNF

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks